Aquestive Therapeutics, Inc. AQST Anaphylm project expenses — R&D
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s anaphylm project expenses — r&d.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s anaphylm project expenses — R&D?
- Aquestive Therapeutics, Inc. (AQST) reported anaphylm project expenses — R&D of $1.09M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s anaphylm project expenses — R&D changed year-over-year?
- Aquestive Therapeutics, Inc.'s anaphylm project expenses — R&D decreased by 56.4% year-over-year, from $2.49M to $1.09M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s anaphylm project expenses — R&D?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s anaphylm project expenses — R&D has grown at a -0.1% compound annual growth rate (CAGR), from $5.83M to $5.82M.
- What does anaphylm project expenses — R&D mean?
- This metric represents the direct research and development expenditures allocated specifically to the Anaphylm product candidate. It captures the costs associated with clinical trials, regulatory filings, and formulation development required to bring this therapeutic for severe allergic reactions to market. Monitoring these expenses provides insight into the company's capital allocation toward its high-priority pipeline assets and the progress of its commercialization timeline.